Top

Shulin Li, PhD

Department of Pediatrics, Division of Pediatrics

Present Title & Affiliation

Primary Appointment

Scientific Director of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Scientific Director of Pediatrics - Research, The University of Texas MD Anderson Cancer Center

Academic Mentoring Program Connector of Pediatrics - Research, The University of Texas MD Anderson Cancer Center

W. T. and Louise Jarrett Moran Distinguished Chair in Pediatric Oncology, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

Education & Training

Degree-Granting Education

1993	Washington State University, Pullman, Washington, US, Ph.D
1985	Shanxi State University, Shanxi, CN, BS

Postgraduate Training

1993-1997

Post doctorate, Molecular Immunology, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Experience & Service

Faculty Academic Appointments

Chair, Department of Institutional Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2019

Lab Program Director, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2025

Paula & Milton Endowed Professor, Louisiana State University, Baton Rouge, LA, 2007 - 2010

Intramural Institutional Committee Activities

Member, Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 2002 - Present

Extramural Institutional Committee Activities

Member, CSO Sustainability of Research Team, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, CSO People and Talent Management Team, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, MDACC Functional Genomics Core (previously, ShRNA and ORFeome Core), The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Pediatric Division Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

Reviewer, Basic Research Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Decisive Discovering Focus Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Endowed Positions and Awards Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Team Leader, Divisional Team Leader Meeting, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, CCH Executive Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Mock Study Section Reviewer, Internal Review Study Section (INTEREST), The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Intellectual property task force, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Committee Member, Promotion Tenure Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2018

Panel Member, Mock Study Section, The University of Texas MD Anderson Cancer Center, 2014

Representative for Pediatric Division, IREC, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Representative for Pediatric Division, Research Council, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Technology Task Force Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2019

Interviewing Committee Member, MD, PhD Review Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Reviewer, Clinical Research Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Editorial Activities

Associate Editor, Frontiers in Oncology and Frontiers in Immunology, 2022

Editorial Board Member, Journal of Clinical Gastroenterology and Hepatology, 2014 - Present

Editorial Board Member, Austin Journal of Pediatrics, 2014 - Present

Editorial Board Member, Austin Biomarkers & Diagnosis, 2014 - Present

Editorial Board Member, Journal of Hematology and Oncology Research, 2014

Editorial Board Member, Austin Journal of Lung Cancer Research, 2014 - Present

Board Member, World Journal of Hepatology, 2013 - Present

Editorial Board Member, Scientific Reports, 2011 - Present

Editor in Chief, Biological Procedure Online, 2009 - Present

Editorial Board Member, Molecular Biotechnology, 2007 - Present

Honors & Awards

2020	Mentoring Award, MD Anderson
2018	President’s Recognition for Faculty Excellence in Education Award, MD Anderson
2017	Presidents Recognition for Faculty Excellence in Research Award, MD Anderson
2007	Distinguished Faculty Scholar Award, School of Veterinary Medicine, Louisiana State University
2005	Pfizer Award for Research Excellence

Professional Memberships

Cancer R & D Conference

2022 - Present

UC San Diego U54 Grant

2019 - Present

MD Anderson Leukemia Section Chief Recruitment Committee Chair

2019 - Present

FGC Internal Advisory Board

2019 - Present

MD Anderson Cancer Center

2018

International Colloquium on Cancer Research

2017

M D Anderson Cancer Center

2017 - Present

Committee on Publication Ethics (COPE)

2015 - Present

American Society of Gene Cell Therapy (ASGCT)

2012 - 2014

The University of Texas MD Anderson Cancer Center

2012 - Present

American Society of Gene Cell Therapy (ASGCT)

2011 - 2014

University of Texas MD Anderson Cancer Center

2011 - Present

Merck-Merial Veterinary Scholars Program Symposium

2011 - Present

American Society of Gene Cell Therapy (ASGCT)

2008 - 2011

Merck-Merial Veterinary Scholars Program

2006

American Association of Cancer Research

1999 - Present

American Society of Gene Therapy

1999 - Present

RNA Society

1993 - 1998

American Association for the Advancement of Science

1993 - Present

Selected Presentations & Talks

Local Presentations

2024. Tumor antigen spreading and Stroma disrupting T cell Therapy—The invention of. Invited. Enjoy Science Webinar Series. Houston, Texas, US.
2021. Sarcoma Seminar Series. Conference. Sarcoma Seminar Series. Houston, TX, US.
2021. Potential Immune Therapy Candidates for Sarcomas. Invited. Potential Immune Therapy Candidates for Sarcomas, US.
2021. Novel Cancer Immune Therapy Candidates: Next Wave?. Conference. Novel Cancer Immune Therapy Candidates: Next Wave?. Houston, TX, US.
2019. Cancer Immune Therapy meets engineering: where we were/are/will be. Invited. Cancer Immune Therapy meets engineering: where we were/are/will be. Houston, TX, US.
2019. The success of cancer immune therapy is about delivery: the lessons learnt from my 20 years lab journey. Conference. The success of cancer immune therapy is about delivery: the lessons learnt from my 20 years lab journey. Houston, TX, US.
2019. A 20 Year Lab Journey in Cancer Therapy: Where we were/are/will be. Conference. A 20 Year Lab Journey in Cancer Therapy: Where we were/are/will be. Houston, TX, US.
2018. Effective Immune Therapy for Overcoming Heterogeneity and T Cell Penetration in Solid Tumors. Conference. Effective Immune Therapy for Overcoming Heterogeneity and T Cell Penetration in Solid Tumors. Houston, TX, US.
2018. Impact of the Immune Checkpoint Regulator Fgl2 on Brain Tumor Progression. Conference. Impact of the Immune Checkpoint Regulator Fgl2 on Brain Tumor Progression. Houston, TX, US.
2017. Lay Language Lecture of CTC. Conference. Lay Language Lecture of CTC. Houston, TX, US.
2017. FGL2 Immunosuppressive Mechanisms in GBM. Conference. FGL2 Immunosuppressive Mechanisms in GBM. Houston, TX, US.
2017. Divisional Research Showcase. Conference. Divisional Research Showcase. Houston, TX, US.
2016. Circulating tumor cells for Leiomyosarcoma. Conference. Circulating tumor cells for Leiomyosarcoma. Houston, TX, US.
2015. Innovative approaches for improving cancer immune therapy: Regulation of immune suppressive and effector cells for cancer and sepsis treatment. Conference. Innovative approaches for improving cancer immune therapy: Regulation of immune suppressive and effector cells for cancer and sepsis treatment. Houston, TX, US.
2014. Cell Surface Vimentin Targeted Antibody for Capturing and Detecting Circulating Tumor Cells. Conference. Cell Surface Vimentin Targeted Antibody for Capturing and Detecting Circulating Tumor Cells. Houston, TX, US.
2014. Mobilize NKG2D immune surveillance system for suppressing tumor growth and inhibiting tumor metastasis. Conference. Mobilize NKG2D immune surveillance system for suppressing tumor growth and inhibiting tumor metastasis. Houston, TX, US.
2014. A mislocalized protein serves as a perfect target for CTC capture and numeration. Invited. A mislocalized protein serves as a perfect target for CTC capture and numeration. Houston, TX, US.
2013. Detection of circulating tumor cells (CTC) in sarcoma. Conference. Detection of circulating tumor cells (CTC) in sarcoma. Houston, TX, US.
2013. Targeted therapy for suppressing Treg induction. Conference. Targeted therapy for suppressing Treg induction. Houston, TX, US.
2012. Inductible tumor-specific immune surveillance signal. Conference. Inductible tumor-specific immune surveillance signal. Houston, TX, US.
2012. IL-30 alleviates drug induced metastatic colon-liver toxicity. Conference. IL-30 alleviates drug induced metastatic colon-liver toxicity. Houston, TX, US.
2012. Dear Cat is Alive-Targeted IL12 Gene Therapy for Colon and Metastatic Tumors. Conference. Dear Cat is Alive-Targeted IL12 Gene Therapy for Colon and Metastatic Tumors. Houston, TX, US.
2012. IL30-A novel anti-inflammatory cytokine for prevention and treatment of liver injury. Invited. IL30-A novel anti-inflammatory cytokine for prevention and treatment of liver injury. Houston, TX, US.
2012. IL30-A novel anti-inflammatory cytokine for prevention and treatment of liver injury. Conference. IL30-A novel anti-inflammatory cytokine for prevention and treatment of liver injury. Houston, TX, US.
2011. Tumor-Targeted IL-12 and GlioPulser:Two Novel Therapeutic Candidates Against Brain Tumors. Conference. Tumor-Targeted IL-12 and GlioPulser:Two Novel Therapeutic Candidates Against Brain Tumors. Houston, TX, US.
2011. Safe IL12 Gene Therapy for Lung Metastasis. Conference. Safe IL12 Gene Therapy for Lung Metastasis. Houston, TX, US.
2011. IL30 therapy for liver toxicity. Conference. IL30 therapy for liver toxicity. Houston, TX, US.
2011. Tumor-targeted Cytokine Gene Therapy for Inhibiting Lung Metastasis. Conference. Tumor-targeted Cytokine Gene Therapy for Inhibiting Lung Metastasis. Houston, TX, US.
2010. Curing of Tumor-bearing canine using bleomycin and IL-12 electro-Chemo-gene therapy. Conference. Curing of Tumor-bearing canine using bleomycin and IL-12 electro-Chemo-gene therapy. Houston, TX, US.
2010. Immune Therapy for Malignancy. Conference. Immune Therapy for Malignancy. Houston, TX, US.
2009. Targeted immune/chemotherapy for tumors: application and mechanism. Invited. Targeted immune/chemotherapy for tumors: application and mechanism. Houston, TX, US.

Regional Presentations

2012. Interleukin 12 electroporation gene therapy for augmenting chemotherapy-mediated tumor regression in dogs: Dirty Personalized Vaccine. Invited. San Diego, CA, US.
2009. Tumor Targeted Immune therapy. Invited. Lubbock, TX, US.
2009. Tumor Targeted Immune Therapy. Invited. Lubbock, TX, US.

National Presentations

2026. Distinguished Keynote Speaker. Invited. San Francisco, California, US.
2025. Physical and biological approaches for gene and T cell delivery against solid tumors. Invited. Chicago, IL, US.
2024. Is induction of tumor relapse free brains an illusion?. Invited. Los Angeles, California, US.
2023. Induction of Brain Resident Tumor-Specific Memory T (BTrm) Cells: A Novel Weapon for Preventing GBM Tumor Relapse?. Conference. Induction of Brain Resident Tumor-Specific Memory T (BTrm) Cells: A Novel Weapon for Preventing GBM Tumor Relapse?. Houston, TX, US.
2023. Fgl2-targeted and attIL12-based T cell vaccine: Booster of current immune therapy. Invited. Excellence in Cancer Research Seminar Series. Oklahoma City, OK, US.
2022. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. Conference. Immunology 2022. Portland, OR, US.
2022. Cell Surface Vimentin-Positive Circulating Tumor Cells May Predict Disease Relapse Post Hematopoietic Stem Cell Transplantation or Cellular Therapy in Patients with Hematological Malignancies. Conference. Cell Surface Vimentin-Positive Circulating Tumor Cells May Predict Disease Relapse Post Hematopoietic Stem Cell Transplantation or Cellular Therapy in Patients with Hematological Malignancies. Salt Lake City, UT, US.
2021. Novel Cancer Immune Therapy candidates: future plan. Invited. Philadelphia, PA, US.
2020. Automated Capture of CSV+ CTCs across tumor types: A Tool for Early Detection of HCC?. Conference. The NCI early HCC detection consortium, US.
2020. Overview of liquid biopsy-based approaches for detecting organ failure: progress vis circulating cell detection. Conference. Bridging Knowledge Gaps: “Extracorporeal Therapies for Pediatric Cellular Therapy Patients”. Houston, TX, US.
2019. Four novel cancer immune therapy candidates for clinical applications: lessons and success strategy learnt from my 20 years lab journey. Invited. Charleston, SC, US.
2019. Four immune therapy candidates for clinical trials against solid tumors. Invited. Charleston, SC, US.
2019. A 20 Year Lab Journey in Immune Therapy and Biology: Cancer and Sepsis. Invited. New Orleans, LA, US.
2019. GAP Conference. Conference. Pediatric Session. Houston, TX, US.
2019. FGL2 expression by tumor cells in the CNS impairs systemic adaptive antitumor immune response by suppressing CD103+ dendritic cell differentiation. Conference. GCCRI Symposium. San Antonio, TX, US.
2018. Multiple Immune therapy approaches for treating tumors in mice and dogs. Conference. Multiple Immune therapy approaches for treating tumors in mice and dogs. Lebanon, NH, US.
2018. Macrophage-Like Circulating Tumor Cells for Prognosis of Metastasis. Conference. Macrophage-Like Circulating Tumor Cells for Prognosis of Metastasis. Boston, MA, US.
2018. Simple Therapeutic Approach for Overcoming Solid Tumor Heterogeneity and Boosting T Cell Infiltration/Function. Conference. Simple Therapeutic Approach for Overcoming Solid Tumor Heterogeneity and Boosting T Cell Infiltration/Function. Boston, MA, US.
2018. Cell-surface vimentin-positive macrophages like CTC's as novel biomarkers of metastatic gastrointestinal stromal tumors. Conference. Cell-surface vimentin-positive macrophages like CTC's as novel biomarkers of metastatic gastrointestinal stromal tumors. Chicago, IL, US.
2018. CHP-IL12 combined with surgery suppresses tumor metastasis and prolongs survival. Conference. CHP-IL12 combined with surgery suppresses tumor metastasis and prolongs survival. Chicago, IL, US.
2018. CRISPR9-mediated FGL2-KO in tumor cells impairs tumor progression in brain and triggers antitumor immune memory systematically via NF-kB dependent Batf3 expression in DC's. Conference. CRISPR9-mediated FGL2-KO in tumor cells impairs tumor progression in brain and triggers antitumor immune memory systematically via NF-kB dependent Batf3 expression in DC's. Chicago, IL, US.
2017. NKG2D Ligand-inducing immune therapy plus NKG2D+CD8+T cell therapy overcomes chemoresistance in tumors. Conference. SITC. National Harbor, MD, US.
2017. Immune suppression in CNS tumors in childhood cancers. Conference. Sonora Cancer Research Center Mexico and US. San Diego, CA, US.
2017. The Challenges and solutions of solid tumor immunotherapy. Invited. Cancer Center Grand Rounds. Columbia, MO, US.
2017. The Challenges and solutions of solid tumor immunotherapy. Invited. MCW Cancer Center Dept. of Dermatology. Milwaukee, WI, US.
2017. Converting heterogenic solid tumors to express the homogenous immune surveillance ligand to overcome tumor resistance to immune therapy. Conference. Molecular Therapeutics of Cancer Research. Burlington, VT, US.
2017. Opportunity for utilizing CTC technology to serve as a marker of immune therapy. Conference. Biomarkers and Immuno-Oncology World Congress. Philadelphia, PA, US.
2016. Challenges and potential solutions of cancer immune therapy. Invited. Department of Chemistry Grand Rounds. Washington, DC, US.
2016. CXCL9, CXCL10 and 1FN&[gamma] favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment. Conference. Immunology 2016. Seattle, WA, US.
2016. FGL2 promotes tumor progression via inducing TIGIT expression on T cells in tumor microenvironment of glioma. Conference. Immunology 2016. Seattle, WA, US.
2015. Cell Surface Vimentin Serves as Markers and Targets for EMT, Stem Cancer Cell and Metastatic Cells. Conference. Cell Surface Vimentin Serves as Markers and Targets for EMT, Stem Cancer Cell and Metastatic Cells. Austin, TX, US.
2015. FGL2 as a multi-modality regulator of tumor-mediated immune suppression. Conference. FGL2 as a multi-modality regulator of tumor-mediated immune suppression. San Antonio, TX, US.
2015. IL30: A biological cytokine provides hepatic protection in chronic inflammation mediated liver fibrosis. Conference. OMICS Group Conferences. Orlanda, FL, US.
2015. Cell and gene therapy mediated immune tolerance: Basic and translational advances. Conference. 18th Annual Meeting. New Orleans, LA, US.
2015. Mechanisms of Pro-Inflammatory Diseases. Conference. Olympic Valley, CA, US.
2015. Safety and efficacy of tumor-targeted interleukin 12 gene therapy for the treatment of local and metastatic cancers. Conference. 18th Annual Meeting. New Orleans, LA, US.
2014. Mis-localized protein for circulating tumor cell capture and detection in sarcomas and beyond. Conference. Mis-localized protein for circulating tumor cell capture and detection in sarcomas and beyond. Las Vegas, NV, US.
2014. A tumor specific cell surface protein localization for diagnosis metastasis and tumor resistance across different types of tumors. Conference. A tumor specific cell surface protein localization for diagnosis metastasis and tumor resistance across different types of tumors. Las Vegas, NV, US.
2013. NKG2D induction: therapeutics and mechanism. Invited. New Orleans, LA, US.
2013. Electroporation-mediated Chemo-Gene Therapy in Canine Cancer Patients. Conference. Electroporation-mediated Chemo-Gene Therapy in Canine Cancer Patients. Boston, MA, US.
2012. BlioMetaPulser for treating metastatic tumors and glioblastoma. Conference. BlioMetaPulser for treating metastatic tumors and glioblastoma. San Diego, CA, US.
2012. Tumor-targeted elmmune Therapy. Invited. Columbus, OH, US.
2011. Targeted IL-12 gene therapy for lung metastasis. Invited. Blue Bell, PA, US.
2010. lmmune Therapy for Improving Tumor Microenvironment and Therapeutic Efficacy Against Tumors. Invited. Pittsburgh, PA, US.
2008. Experience of using electroporation chemogene therapy for treating spontaneous tumors in dogs. Invited. Boston, MA, US.
2008. Experience of using electroporation chemogene therapy for treating spontaneous tumors in dogs. Conference. Experience of using electroporation chemogene therapy for treating spontaneous tumors in dogs. Boston, MA, US.
2007. Programmed cytokine gene therapy. Conference. Programmed cytokine gene therapy. Seattle, WA, US.
2007. Systemic sequential cytokine gene therapy for treating residual tumors. Invited. Seattle, WA, US.
2007. Systemic sequential cytokine gene therapy for treating residual tumors. Conference. Systemic sequential cytokine gene therapy for treating residual tumors. Seattle, WA, US.
2006. DNA vaccination and systemic programmed cytokine gene therapy for treating tumors. Conference. DNA vaccination and systemic programmed cytokine gene therapy for treating tumors. Baton Rouge, LA, US.
2006. DNA vaccination and systemic programmed cytokine gene therapy for treating tumors. Invited. Baton Rouge, LA, US.
2006. Application and mechanism of doxorubicin-combined IL-12 gene therapy. Invited. Charleston, SC, US.
2006. Application and mechanism of doxorubicin-combined IL-12 gene therapy. Conference. Application and mechanism of doxorubicin-combined IL-12 gene therapy. Charleston, SC, US.
2005. IL-12 electrogenetherapy: application and mechanism. Conference. IL-12 electrogenetherapy: application and mechanism. New Orleans, LA, US.
2005. IL-12 electrogenetherapy: application and mechanism. Invited. New Orleans, LA, US.
2005. Bleomycin and IL-12 electrochemogene therapy for treating cancer. Conference. Bleomycin and IL-12 electrochemogene therapy for treating cancer. Shreveport, LA, US.
2005. Bleomycin and IL-12 electrochemogene therapy for treating cancer. Invited. Shreveport, LA, US.
2005. IL-12 electrogenetherapy for treating tumors. Invited. New Orleans, LA, US.
2005. IL-12 electrogenetherapy for treating tumors. Conference. Gene Therapy Program and Department of Pharmacology. New Orleans, LA, US.
2004. IL-12 electro-chemo-gene therapy for treating malignancy. Invited. Baton Rouge, LA, US.

International Presentations

2024. AttIL12-T Cell Therapy For Simultaneously Disrupting Stroma/tumors And Induction Of Endogenous TCR-T Cells. Invited. Seoul, KR.
2024. attIL12-T Cell Therapy: A Novel Class of Stroma/ECM Disrupting Cytokine/Cell Therapy for Treating Solid Tumors. Invited. Nagoya, JP.
2022. attIL12-T cell therapy: CAR-T or TCR-T?. Conference, CN.
2021. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance. Conference. 40th World Cancer Conference - Webinar, US.
2020. Pilot Study of Circulating Tumor Cells in Pediatric High-Grade Brain Tumors. Conference. Nagano, JP.
2020. Cancer Conference 2026. Invited. San Francisco, US.
2020. IL6 reprograms β2SP+/- deficient stem cells into 'seed' metastatic cancer stem in per-neoplastic livers. Conference. Stem Cell Research 2020. Tokyo, JP.
2019. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma, Poster Presentation. Conference. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma, Poster Presentation. Tokyo, JP.
2017. The Challenge and possible solution of solid tumor immune therapy. Invited. Shenyang, CN.
2017. Treg Cell Regulation/How to write high impact article/How to select research project/The role of IL30 and IL6 in livers. Invited. The Liver Transplantation Center. Nanjing, CN.
2017. The Challenge and possible solution of solid tumor immune therapy. Invited, CN.
2016. Treg initiation mechanism and biological function. Conference. Treg initiation mechanism and biological function. Shanghai, CN.
2015. Early detection of tumor relapse and profiling of tumor resistance via a universal CTC capture system. Conference. 6th Annual World DNA & Genome Day 2015. Nanjing, CN.
2014. Inducible NKG2D immune surveillance for tumor treatment. Conference. Jilin University. Changchun, CN.
2013. NKG2D restoration therapy for metastatic tumors. Conference. NKG2D restoration therapy for metastatic tumors. Shanghai, CN.
2013. NKG2D restoration therapy for metastatic tumors. Invited, CN.
2013. A universal circulating tumor cell detection tool for monitoring tumor metastasis. Conference. A universal circulating tumor cell detection tool for monitoring tumor metastasis. Haikou, CN.
2013. Electroporation IL30 gene therapy for treating liver injury. Conference. Electroporation IL30 gene therapy for treating liver injury. Osaka, JP.
2012. Tumor targeted electroporation immune therapy for cancer. Conference. Tumor targeted electroporation immune therapy for cancer. Shanghai, CN.
2011. Electroporation Immune Therapy for Bone Malignancy. Invited, CN.

Less

Grant & Contract Support

Date:	2025 - 2030
Title:	Targeting RNF2 to synergize with oncolytic immunovirotherapy to induce anti-cancer immunity in medulloblastoma
Funding Source:	National Institutes of Health
Role:	Co-PI
ID:	GRANT14347407

Date:	2025 - 2030
Title:	MD Anderson Sarcoma SPORE, Project 2: Adoptive Cell Therapies for Chordomas
Funding Source:	National Institute of Health
Role:	PI
ID:	P50CA302482

Date:	2024 - Present
Title:	Novel Therapies for Osteosarcoma
Funding Source:	CPRIT MIRA
Role:	Project Leader
ID:	RP240440

Date:	2023 - 2028
Title:	attIL12 modified TIL transfer for enhanced tumor infiltration in autologous liposarcoma PDX tumors
Funding Source:	NIH/R01
Role:	Collaborator
ID:	PA-20-185

Date:	2023 - 2027
Title:	T Cell Membrane-Anchored Tumor Targeted IL12 (ATTIL12)-T Cell Therapy In Subjects With Advanced/Metastatic Sarcoma
Funding Source:	American Cancer Society (ACS)
Role:	CO-I
ID:	SRA-22-194-01-SRA

Date:	2021 - 2026
Title:	Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Funding Source:	NIH/NINDS
Role:	PI
ID:	R01NS122857

Date:	2021 - 2026
Title:	Gene-product auto-targeting to tumor vessels
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA120895

Date:	2018 - 2023
Title:	Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01EB026291

Date:	2018 - 2023
Title:	Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	1 U01 CA230690-01

Date:	2018 - 2023
Title:	Genome-wide Analysis of Hepatocellular Carcinoma
Funding Source:	George Washington University
Role:	Principal Investigator-MDACC
ID:	FP00002107

Date:	2018 - 2023
Title:	Inducible ligand for breast tumor-targeted delivery of T cells
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00002672

Date:	2018 - 2022
Title:	Inducible NKG2D ligand for tumor-targeted delivery of NKG2D T cells and for overcoming the challenge of tumor heterogeneity
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	FP00002360

Date:	2018 - 2020
Title:	CSV-CTC for prognosis of Neuroblastoma relapse and monitoring treatment response
Funding Source:	Pediatric Cancer Research Foundation
Role:	PI
ID:	FP0002119

Date:	2017 - 2020
Title:	Prognosis of relapse for mesenchymal tumors via CSV CTC: preparation toward FDA approval
Funding Source:	NIH/NCI
Role:	PI

Date:	2017 - 2022
Title:	Cellular and Molecular Mechanisms of Gastrointestinal Cancers
Funding Source:	George Washington University
Role:	Project Leader

Date:	2017 - 2020
Title:	Targeting a novel cell surface alteration for therapy of acute leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2017 - 2022
Title:	Develop CTC capture technology for both mesenchymal and nonmesenchymal tumors
Funding Source:	NIH/NCI
Role:	PI

Date:	2017 - 2019
Title:	Predicting relapse of post remission NB patients via novel CTC marker
Funding Source:	NIH/NCI
Role:	PI

Date:	2017 - 2020
Title:	Balancing T-Cell Function and Metabolism for Immunotherapy
Funding Source:	Department of Defense (DOD)
Role:	Principal Investigator-MDACC
ID:	FP00003157

Date:	2017 - 2022
Title:	A universal and tumor-specific CTC capture tool: generation and novel utility
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2019
Title:	Development of the first automated and universal CTC capture system toward precision medicine in pediatric/adolescent cancer patients
Funding Source:	V Foundation for Cancer Research
Role:	PI

Date:	2016 - 2017
Title:	NO TITLE PROVIDED
Funding Source:	Biotechnology
Role:	Creator

Date:	2016 - 2021
Title:	Automatic and Universal CTC Detection Chip for Noval Clinical Utility
Funding Source:	Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment
Role:	PI

Date:	2016 - 2021
Title:	Fgl-2 targeted therapy for reversing multi-modality immune suppression
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2023
Title:	Fgl-2 targeted therapy for reversing multi-modality immune suppression
Funding Source:	NIH/NCI
Role:	Multi-PI
ID:	R01CA203493

Date:	2016 - 2023
Title:	A novel immune suppressive blocker for treating metastatic tumors
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2018
Title:	Interleukin 12 Gene Transfer by Irreversible Electroporation for SCCHN
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2021
Title:	Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis
Funding Source:	University of California-San Diego
Role:	Multi-PI
ID:	R01CA200574

Date:	2016 - 2017
Title:	Sarcoma CTC Analysis from Frozen PBMC
Funding Source:	Immune Design
Role:	PI

Date:	2016 - 2018
Title:	CTC for assessing tumor relapse in neuroblastoma
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2018
Title:	Exploring the potential utility of a universal sarcoma CTC assay
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2019
Title:	Induction of NKG2D ligand for treating metastatic tumors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160012-Y1

Date:	2015 - 2018
Title:	Targeting a novel cell surface alteration for therapy of acute myeloid leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2015 - 2016
Title:	NO TITLE PROVIDED
Funding Source:	Biotechnology
Role:	Creator

Date:	2015 - 2020
Title:	Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury
Funding Source:	NIH/NIDDK
Role:	PI
ID:	1R01DK102767-01A1

Date:	2015 - 2020
Title:	Tumor Specific NKG2D Ligand Induction Immune Therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA196826-01

Date:	2015 - 2017
Title:	Sensitivity/Specificity of the First Universal Sarcoma CTC Detection Tool
Funding Source:	NIH/NCI
Role:	PI

Date:	2015 - 2020
Title:	NO TITLE PROVIDED
Funding Source:	NIH/NCI
Role:	CO-I

Date:	2015 - 2020
Title:	6660 SPORE in Liver Cancer
Funding Source:	NIH/NCI
Role:	Project Leader

Date:	2015 - 2020
Title:	Training in Brain Tumor Research
Funding Source:	NIH/NCI
Role:	Faculty Mentor

Date:	2015 - 2016
Title:	Precision-Targeted Immunotherapy for Glioblastoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Project Leader

Date:	2015 - 2020
Title:	Gene Therapy-Facilitated RBC Membrane-Cloaked Nanotherapeutics for Osteosarcoma
Funding Source:	NIH/NCI
Role:	CO-I
ID:	1R01CA188079-01A1

Date:	2015 - 2019
Title:	CTCs for assessing and preventing tumor relapse against pediatric sarcoma/neuroblastoma metastasis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2014 - 2015
Title:	Colon CTC Analysis
Funding Source:	Parsortx
Role:	Co-PI

Date:	2014 - 2019
Title:	Interleukin-27 Gene Delivery for Disruptive Tumor/Bone Malignant Interactions
Funding Source:	NIH/NCI
Role:	PI

Date:	2014 - 2017
Title:	Targeted therapy for suppressing Treg inducers
Funding Source:	M D Anderson Cancer Center
Role:	Project Leader

Date:	2014 - 2017
Title:	Induction of NKG2D Ligand for Treating Metastatic Tumors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2014 - 2019
Title:	Restoring NKG2D ligand on tumor cells surface
Funding Source:	NIH/NCI
Role:	PI

Date:	2014 - 2019
Title:	NKG2D Ligand Inducing Gene Therapy for Overcoming Tumor Resistance to Doxorubicin
Funding Source:	NIH/NCI
Role:	PI

Date:	2014 - 2016
Title:	Exploration of a Universal EMT Tumor Cell Isolation Tool
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21CA193272-01

Date:	2013 - 2018
Title:	Tumor-specific NKG2D ligand restoration-therapeutics and mechanism
Funding Source:	NIH/NCI
Role:	PI

Date:	2013 - 2018
Title:	Tumor Targeted Drug/Gene Delivery for Metastatic Osteosarcoma in the Lungs
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA178005

Date:	2013 - 2016
Title:	MR Electrical Impedance Tomography for Planning Low Voltage RF Therapy of Glioblastomas
Funding Source:	Mike Hogg Foundation
Role:	Co-PI

Date:	2012 - 2015
Title:	Aerosol-based Triple Tumor-targeted Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2012 - 2017
Title:	Attract Investigators with Innovative Translational Projects in Alcoholic Hepatitis
Funding Source:	NIH/NCI
Role:	PI
ID:	1U01AA021911-01

Date:	2012 - 2016
Title:	Triple Metastatic Lung Tumor - Targeted Immunology Therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA170224(MPI)

Date:	2012 - 2017
Title:	Translational Research Training for Pediatrics hematology/Oncology Fellows
Funding Source:	Ruth L. Kirchstein National Research Service Award (NRSA) Institutional Research Grants
Role:	Co-PI
ID:	CA16009 PA-11-184

Date:	2012 - 2019
Title:	Gene-product auto-targeting to tumor vessels
Funding Source:	NIH/NCI
Role:	PI
ID:	4R01CA120895

Date:	2011 - 2014
Title:	Chemical free technology (UV and electroporation) for conjugating siRNA/CpG ODN to tumor-targeted antibody for triggering tumor-specific immune
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2011 - 2014
Title:	Targeted Chemo-Immunotherapy for Osteosarcoma Lung Metastases
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2011 - 2016
Title:	Translational Research Training for Pediatric Hematology/Oncology Fellows
Funding Source:	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant
Role:	Co-PI
ID:	PA-10-036

Date:	2010 - 2015
Title:	A recombinant varicella vaccine for protection against mucosal SIV infection
Funding Source:	NIH/NCI
Role:	PI

Date:	2010 - 2017
Title:	IL12 Gene Therapy for Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tumors in Dogs
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA142855

Date:	2010 - 2011
Title:	Gene-product auto-targeting to tumor vessels
Funding Source:	NIH/NCI
Role:	PI
ID:	3R01CA120895-04S1

Date:	2010 - 2017
Title:	MD Anderson SPORE in Hepatocellular Cancer
Funding Source:	MD Anderson Cancer Center
Role:	Collaborator
ID:	NCI/NIH, P50CA165968

Date:	2010 - 2015
Title:	Elimination of residual malignancy by programmed systemic cytokine gene therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	7R01CA098928

Date:	2008 - 2010
Title:	Novel gene delivery and expression system
Funding Source:	NIH/NIBIB
Role:	PI
ID:	R21EB007208

Date:	2008 - 2016
Title:	Cellular and Molecular Mechanisms of Gastrointestinal Cancers
Funding Source:	NIH/NCI
Role:	(Project 2 leader, Core 2 leader, MDA site leader)
ID:	5P01CA130821

Date:	2008 - 2010
Title:	Research Training in Experimental Medicine and Pathology
Funding Source:	NIH/NCRR
Role:	Mentor
ID:	T32 RR021309-01

Date:	2008 - 2009
Title:	(Bridge fund) Programmed Cytokine Gene Therapy
Funding Source:	NIH/NCI
Role:	PI

Date:	2008 - 2010
Title:	p21CDK2AP1 regulation of normal and anaplastic growth
Funding Source:	NIH/NCI
Role:	Mentor
ID:	3K01CA117921-05S1

Date:	2007 - 2020
Title:	Gene-product auto-targeting to tumor vessels
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA120895

Date:	2007 - 2008
Title:	IL12 Gene Therapy Promoting Tumor Vaccine
Funding Source:	Louisiana State Gene Therapy Consortium
Role:	PI

Date:	2007 - 2008
Title:	Programmed Therapy for Residual Malignancy Post Surgery
Funding Source:	Louisiana State Cancer Consortium/Competitive Award
Role:	PI

Date:	2005 - 2010
Title:	Louisiana Technology Network
Funding Source:	NIH/NCI
Role:	Mentor

Date:	2004 - 2006
Title:	Prostate Cancer Gene Therapy
Funding Source:	Internal CORPS grant for cancer
Role:	CO-I

Date:	2002 - 2005
Title:	Tumor-targeted electroporation gene therapy
Funding Source:	NIH/NIDCR
Role:	PI
ID:	7 R21 DE015167-02

Date:	2002 - 2009
Title:	Elimination of residual malignancy by programmed systemic cytokine gene therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	2R56CA098928-07A1

Date:	2002 - 2007
Title:	Electro-injection of IL-12 DNA to Muscle for Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA098928-06

Date:	2002 - 2007
Title:	Electroinjection of IL-12 DNA to muscle for cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA88998

Date:	2002 - 2005
Title:	Tumor-targeted gene therapy
Funding Source:	NIH/NIDCR
Role:	PI

Date:	2001 - 2002
Title:	Interlleukin 12 (IL12) electroporation gene therapy for SCC
Funding Source:	Pardee Foundation
Role:	PI

Date:	2000 - 2002
Title:	Intratumoral IL-12 Electrogenetherapy
Funding Source:	Elisa Pardee Foundation
Role:	PI

Date:	1998 - 2000
Title:	Linkage of Nonsense Codons and RNA Splicing
Funding Source:	National Science Foundation (NSF)
Role:	Co-PI
ID:	MCB-9808936

Date:	1996 - 1998
Title:	Regulation of T Cell Receptor Expression
Funding Source:	NIH/NIAID
Role:	PI
ID:	1F32GM018128-01

Title:	Gene Therapy-Facilitated RBC Membrane-Cloaked Nanotherapuetics for Osteosarcoma
Funding Source:	NIH/NCI
Role:	PI

Title:	Combating Intratumoral cancer cell heterogeneity in Ewing sarcoma by co-targeting the EWS-FLI1 fusion protein and epigenetic mediators of resistance
Funding Source:	NIH/NCI
Role:	Co-PI

Title:	Triple Metastatic Lung Tumor-Targeted Immune Therapy
Funding Source:	NIH/NCI
Role:	CO-I

Title:	Cellular and Molecular Mechanisms of Gastrointestinal Cancers
Funding Source:	George Washington University
Role:	PI
ID:	P01CA130821

Selected Publications

Peer-Reviewed Articles

Zhang S, Jin Y, Jia Z, Xia X, Li Y, Wang Q, Wang J, Wang J, Chandra J, Friedman GK, Li S. Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. Cancer Lett:218215, 2025. e-Pub 2025. PMID: 41380903.
Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A 122(41):e2507542122, 2025. e-Pub 2025. PMID: 41052334.
Kim EJ, Wang Y, Chen YL, Ma M, Liu P, Bacabac MS, Zhou J, Fry CJ, Hoffman JR, Yu M, Li L, Suzuki A, Li S, Xu W. CARM1-mediated MAP2K4 methylation potentiates the oncogenic functions of MAP2K4 and constitutes a targetable dependency in triple-negative breast cancer. Cancer Res 85(16):3072-3088, 2025. e-Pub 2025. PMID: 40440094.
Jin Y, Jia Z, Xia X, Gordon N, Ludwig JA, Somaiah N, Li S. Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumorinfiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Front Immunol 16, 2025. e-Pub 2025.
Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 12(1):E006991, 2024. e-Pub 2024. PMID: 38199607.
Zaky W, Ragoonanan D, Batth I, Dao L, Wang J, Xia X, Daw NC, Gill JB, Khatua S, Li S. Automated Capture and Analysis of Circulating Tumor Cells in Pediatric, Adolescent and Young Adult Patients with Central Nervous System Tumors. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568669.
Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes N, Yan J, Xia X, Yi S, Dao L, Masopust D, Heimberger A, Li S. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 14(1):735, 2023. e-Pub 2023. PMID: 36759517.
Dao L, Zhao Q, Hu J, Xia X, Yang Q, Li S. A microfluidics-based method for isolation and visualization of cells based on receptor-ligand interactions. PLoS One 17(10), 2022. e-Pub 2022. PMID: 36201506.
Ragoonanan D, Sheikh I, Gupta S, Khazal SJ, Tewari P, Petropoulos D, Li S, Mahadeo KM. Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clin Cancer Res 28(17):3862-3873, 2022. e-Pub 2022. PMID: 35727602.
Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao L, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-anchored and tumor-targeted IL-12 (attIL12)-PBMC therapy for osteosarcoma. Clinical Cancer Research, 2022. e-Pub 2022. PMID: 35727602.
Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao LH, Xia X, Fowlkes NW, Zhang Z, Mahadeo KM, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill J, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman ES, Gorlick R, Daw N, Li S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Frontiers Oncol 11, 2021. e-Pub 2021. PMID: 34956881.
Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. e-Pub 2021. PMID: 33731864.
Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat Commun 12(1):3500, 2021. e-Pub 2021. PMID: 34108491.
Yan J, Zhao Q, Wang J, Tian X, Wang J, Xia X, Ott M, Rao G, Heimberger AB, Li S. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Lett 506:83-94, 2021. e-Pub 2021. PMID: 33676940.
Hu J, Xia X, Zhao Q, Li S. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance. Cancer Lett 502:143-153, 2021. e-Pub 2021. PMID: 33279621.
Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li S. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv 7(5), 2021. e-Pub 2021. PMID: 33571109.
Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight 5(17), 2020. e-Pub 2020. PMID: 32721947.
Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long J, Li S, Curran M, Heimberger AB. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res 26(17):4699-4712, 2020. e-Pub 2020. PMID: 32554515.
Batth IS, Meng Q, Wang Q, Torres KE, Burks J, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
Zhuang J, Duan Y, Zhang Q, Gao W, Li S, Fang RH, Zhang L. Multimodal enzyme delivery and therapy enabled by cell membrane-coated metal-organic framework nanoparticles. Nano Lett 20(5):4051-4058, 2020. e-Pub 2020. PMID: 32352801.
Chen J, Mitra A, Li S, Song S, Nguyen BN, Chen JS, Shin JH, Gough NR, Lin P, Obias V, He AR, Yao Z, Malta TM, Noushmehr H, Latham PS, Su X, Rashid A, Mishra B, Wu RC, Mishra L. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. Cancer Res 80(9):1819-1832, 2020. e-Pub 2020. PMID: 32127355.
Mahadeo K, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, Vittorio J, Angelo J, McArthur J, Schadler K, Chan S, Tewari P, Khazal SJ, Auletta JJ, Choi SW, Shoberu B, Kalwak K, Harden A, Kebriaei P, Abe J, Li S, Moffet JR, Abraham S, Tambaro FP, Kleinschmidt K, Richardson PG, Corbacioglu S. Diagnosis, grading, and treatment recommendations for children, adolescents and young adult patients with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematology 7(1):61-72, 2019. e-Pub 2019.
Hu J, Xia X, Gorlick R, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediatedactivation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene 38(49):7433-7446, 2019. e-Pub 2019. PMID: 31427736.
Mitra, A, Yan, J, Zhang, L, Li &, S. A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure. Translational Research 205:44-50, 2019. e-Pub 2019. PMID: 30399369.
Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103 + dendritic cell differentiation. Nat Commun 10(1):448, 2019. e-Pub 2019. PMID: 30683885.
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. J Allergy Clin Immunol 143(1):346-358.e6, 2019. e-Pub 2019. PMID: 30096390.
Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Research Network CGA, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):442-437, 2018. e-Pub 2018. PMID: 30268436.
Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest 129(1):137-149, 2018. e-Pub 2018. PMID: 30307407.
Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li S. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185, 2018. e-Pub 2018. PMID: 29991446.
Luk BT, Jiang Y, Copp JA, Hu CJ, Krishnan N, Gao W, Li S, Fang RH, Zhang L. Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions. Mol Pharm 15(9):3723-3728, 2018. e-Pub 2018. PMID: 29533668.
Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Davis RE, Huang S, Fuller GN, Uppore Kukkillaya AR, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Journal of the National Cancer Institute 111(3):292-300, 2018. e-Pub 2018. PMID: 29947810.
Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clin Cancer Res 24(12):2920-2934, 2018. e-Pub 2018. PMID: 29391351.
Dibra D, Xia X, Gagea M, Lozano G, Li S. A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS One 13(3):e0193485, 2018. e-Pub 2018. PMID: 29494633.
Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 7(4):e1412909, 2018. e-Pub 2018. PMID: 29632728.
Chen J, Zaidi S, Rao S, Chen JS, Phan L, Farci P, Su X, Shetty K, White J, Zamboni F, Wu X, Rashid A, Pattabiraman N, Mazumder R, Horvath A, Wu RC, Li S, Xiao C, Deng CX, Wheeler DA, Mishra B, Akbani R, Mishra L. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. Gastroenterology 154(1):195-210, 2018. e-Pub 2018. PMID: 28918914.
Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology 7(5):e1420450, 2018. e-Pub 2018. PMID: 29721368.
Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett 403:216-223, 2017. e-Pub 2017. PMID: 28652021.
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19(8):1047-1057, 2017. e-Pub 2017. PMID: 28371827.
Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh H, Rojas CR, Li H, Meng QH, Li S. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget 8(30):49329-49337, 2017. e-Pub 2017. PMID: 28521303.
Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8(+) T Cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. e-Pub 2017. PMID: 28223282.
Mitra A, Yan J, Xia X, Zhou S, Chen J, Mishra L, Li S. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin+/- mice. Hepatology 65(4):1222-1236, 2017. e-Pub 2017. PMID: 27863449.
Dibra D, Mitra A, Newman M, Xia X, Keenan C, Cutrera JJ, Mathis JM, Wang XJ, Myers J, Li S. IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget 7(47):77138-77151, 2016. e-Pub 2016. PMID: 27738312.
Hu J, Batth IS, Xia X, Li S. Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. Oncoimmunology 5(12):e1252012, 2016. e-Pub 2016. PMID: 28123894.
Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li S. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget 7(44):72021-72032, 2016. e-Pub 2016. PMID: 27713131.
Satelli A, Hu J, Xia X, Li S. Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells. J Cancer 7(13):1824-1832, 2016. e-Pub 2016. PMID: 27698922.
Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res 22(15):3876-83, 2016. e-Pub 2016. PMID: 26979394.
Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 6:28910, 2016. e-Pub 2016. PMID: 27363678.
Chen J, Katz L, Munoz NM, Gu S, Shin J, Jogunoori W, Lee MH, Belkin M, Kim SB, White J, Andricovich J, Tzatsos A, Li S, Kim SS, Shetty K, Mishra B, Rashid A, Lee J, Mishra L. Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-β/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Sci Rep 6:30217, 2016. e-Pub 2016. PMID: 27456065.
Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64(5):1128-1136, 2016. e-Pub 2016. PMID: 26767500.
Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. e-Pub 2016. PMID: 27100181.
Luk BT, Fang RH, Hu CM, Copp JA, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics 6(7):1004-11, 2016. e-Pub 2016. PMID: 27217833.
Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in Concert with an Interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 63(3):1000-12, 2016. e-Pub 2016. PMID: 26637970.
Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2016. e-Pub 2016. PMID: 26784546.
Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin+CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer 137(2):491-6, 2015. e-Pub 2015. PMID: 25487874.
Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J Natl Cancer Inst 107(8), 2015. e-Pub 2015. PMID: 25971300.
Cutrera J, King G, Jones P, Gumpel E, Kicenuik K, Xia X, Li S. Safe and Effective Treatment of Spontaneous Neoplasms with Interleukin 12 Electro-Chemo-Gene Therapy. J Cell Mol Med 19(3):664-675, 2015. e-Pub 2015. PMID: 25628149.
Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, and Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899-906, 2015. e-Pub 2015. PMID: 25516888.
Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CK11b positive bone marrow derived stromal cells. Cell Commun Signal 13(14), 2015. e-Pub 2015. PMID: 25889536.
Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem 61(1):259-266, 2015. e-Pub 2015. PMID: 25336717.
Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 60(6):2027-39, 2014. e-Pub 2014. PMID: 25351459.
Lu J, Zhao W, Huang Y, Liu H, Marquez R, Gibbs R, Li J, Venkatarmanan R, Xi L, Li S, Li S. Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier. Mol Pharm 11(11):4164-78, 2014. e-Pub 2014. PMID: 25265550.
Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645-1650, 2014. e-Pub 2014. PMID: 24448245.
Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer 13(34), 2014. e-Pub 2014. PMID: 24565056.
Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biol Proced Online 16(1):3, 2014. e-Pub 2014. PMID: 24495546.
Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Molecular Cancer, 2014. e-Pub 2014.
Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions. Curr Gene Ther 15(1):44-54, 2014. e-Pub 2014. PMID: 25429465.
Denada D, Li S. The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-κB1, STAT3, and CD40/CD154. Cell Commun Signal 11(1):95, 2013. e-Pub 2013. PMID: 24330710.
Fang RH, Hu CM, Chen KN, Luk BT, Carpenter CW, Gao W, Li S, Zhang DE, Lu W, Zhang L. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5(19):8884-8, 2013. e-Pub 2013. PMID: 23907698.
Irwin ME, Nelson LD, Santigiao O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Sornblau SM, Hughes DP, Chandra J. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One 8(8):e70608, 2013. e-Pub 2013. PMID: 23936456.
Shiomitsu K, Xia X, Waite K, Sehgal I, Li S. Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro. Open Journal of Veterinary Medicine 3:29-38, 2013. e-Pub 2013.
Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 43(2):468-79, 2013. e-Pub 2013. PMID: 23225163.
Cutrera J, Johnson B, Ellis L, Li S. Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies. Cancer Lett 329(1):68-73, 2013. e-Pub 2013. PMID: 23111105.
Cutrera J, Dibra D, Xia X, Li S. Intricacies for Post-translational tumor-targeted cytokine gene therapy. Mediators Inflamm 2013:378971, 2013. e-Pub 2013. PMID: 24369443.
Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 55(4):1204-14, 2012. e-Pub 2012. PMID: 22105582.
Flanagan M, Gimble JM, Yu G, Xia X, Bunnell BA, Li S. Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cells. Biol Proced Online 14(1):7, 2012. e-Pub 2012. PMID: 22512891.
Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J Immunol 188(8):3709-15, 2012. e-Pub 2012. PMID: 22407920.
Zolochevska O, Xia X, Williams BJ, Ramsay A, Li S, Figueiredo ML. Sonoporation Delivery of Interleukin-27 Gene Therapy Efficiently Reduces Prostate Tumor Cell Growth In Vivo. Hum Gene Ther 22(12):1537-50, 2011. e-Pub 2011. PMID: 21801027.
Cutrera J, Dibra D, Xia X, Hasan A, Reed S, Li S. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol Ther 19(8):1468-77, 2011. e-Pub 2011. PMID: 21386825.
Flanagan M, Gimble JM, Yu G, Wu X, Xia X, Hu J, Yao S, Li S. Competitive electroporation formulation for cell therapy. Cancer Gene Ther 18(8):579-86, 2011. e-Pub 2011. PMID: 21660061.
Reed SD, Li S. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. Cancer Gene Ther 18(4):265-74, 2011. e-Pub 2011. PMID: 21233859.
Dibra D, Cutrera J, Xia X, Li S. WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells. PLoS One 6(4):e19072, 2011. e-Pub 2011. PMID: 21559505.
Li S. Biological Procedures Online now publishing with BioMed Central. Biol Proced Online 13(1):2, 2011. e-Pub 2011. PMID: 21369533.
Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J, Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS One 6(8):e23270, 2011. e-Pub 2011. PMID: 21853100.
Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Retracted. Cancer Gene Ther 17(8):571-578, 2010. e-Pub 2010. PMID: 20414325.
Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 17(7):457-64, 2010. e-Pub 2010. PMID: 20150931.
Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184(5):2348-54, 2010. e-Pub 2010. PMID: 20139275.
Cutrera J, Dibra D, Xia X, Li S. Enhancement of reporter gene detection sensitivity by insertion of specific mini-peptide-coding sequences. Cancer Gene Ther 17(2):131-140, 2010. e-Pub 2010. PMID: 19713998.
Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res 69(13):5505-13, 2009. e-Pub 2009. PMID: 19549909.
Shiomitsu K, Sajo E, Xia X, Hunley DW, Mauldin GE, Li S, Mauldin GN. Radiosensitivity of canine osteosarcoma cells transfected with wild-type p53 in vitro. Vet Comp Oncol 6(3):193-200, 2008. e-Pub 2008. PMID: 19178679.
Craig R, Cutrera J, Zhu S, Xia X, Lee YH, Li S. Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within or into tumors. Mol Ther 16(5):901-6, 2008. e-Pub 2008. PMID: 18388923.
Zhu S, Li S. Systemic IL-12 gene therapy for treating malignancy via intramuscular electroporation. Methods Mol Biol 423:327-337, 2008. e-Pub 2008. PMID: 18370211.
Torrero M, Li S. Treatment of SCCVII tumors with systemic chemotherapy and Interleukin-12 gene therapy combination. Methods Mol Biol 423:339-349, 2008. e-Pub 2008. PMID: 18370212.
Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 423:319-325, 2008. e-Pub 2008. PMID: 18370210.
Li S. Delivery of DNA into tumors. Methods Mol Biol 423:311-318, 2008. e-Pub 2008. PMID: 18370209.
Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 13(14):4252-60, 2007. e-Pub 2007. PMID: 17634555.
Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, Li S. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 119(9):2113-8, 2006. e-Pub 2006. PMID: 16823840.
Torrero MN, Xia X, Henk W, Yu S, Li S. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 66(8):4461-7, 2006. e-Pub 2006. PMID: 16618773.
Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 12(1):257-63, 2006. e-Pub 2006. PMID: 16397050.
Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 12(5):942-9, 2005. e-Pub 2005. PMID: 15953768.
Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A, Bhardwaj A. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 11(1):112-9, 2005. e-Pub 2005. PMID: 15585412.
Li S, Xia X, Mellieon FM, Liu J, Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9(3):347-54, 2004. e-Pub 2004. PMID: 15006601.
Li S, Hanna E, Breau R, Ratanatharathorn V, Xia X, Suen J. Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs. Br J Cancer 90(5):1093-9, 2004. e-Pub 2004. PMID: 14997212.
Dornhoffer JL, Danner C, Zhou L, Li S. Atrial natriuretic peptide receptor upregulation in the rat inner ear. Ann Otol Rhinol Laryngol 111(11):1040-1044, 2002. e-Pub 2002. PMID: 12450181.
Wang J, Hamilton JI, Carter MS, Li S, Wilkinson MF. Alternatively spliced TCR mRNA induced by disruption of reading frame. Science 297(5578):108-110, 2002. e-Pub 2002. PMID: 12098701.
Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62(13):3722-3728, 2002. e-Pub 2002. PMID: 12097281.
Wang J, Vock VM, Li S, Olivas OR, Wilkinson MF. A quality control pathway that down-regulates aberrant T-cell receptor (TCR) transcripts by a mechanism requiring UPF2 and translation. J Biol Chem 24(277):18489-93, 2002. e-Pub 2002. PMID: 11889124.
Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 94(10):762-8, 2002. e-Pub 2002. PMID: 12011227.
Dornhoffer JL, Danner C, Li S. Natriuretic peptide receptors in the human endolymphatic sac. Arch Otolaryngol Head Neck Surg 128(4):379-83, 2002. e-Pub 2002. PMID: 11926910.
Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 9(6):390-7, 2002. e-Pub 2002. PMID: 11960315.
Mühlemann O, Mock-Casagrande CS, Wang J, Li S, Custódio N, Carmo-Fonseca M, Wilkinson MF, Moore MJ. Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol Cell 8(1):33-43, 2001. e-Pub 2001. PMID: 11511358.
Hanna E, Zhang X, Woodlis J, Breau R, Suen J, Li S. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 8(3):151-7, 2001. e-Pub 2001. PMID: 11332985.
Hanna E, Shrieve DC, Ratanatharathorn V, Xia X, Breau R, Suen J, Li S. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res 61(6):2376-80, 2001. e-Pub 2001. PMID: 11289099.
Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F, Dean DA, Smith LC. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Ther 8(6):494-7, 2001. e-Pub 2001. PMID: 11313829.
Li S, Zhang X, Xia X, Zhou L, Breau RL, Suen J, Hanna EY. Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 8(5):400-407, 2001. e-Pub 2001. PMID: 11313817.
Li S, MacLaughlin FC, Fewell JG, Li Y, Mehta V, French MF, Nordstrom JL, Coleman M, Belagali NS, Schwartz RJ, Smith LC. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems. Gene Ther 6(12):2005-11, 1999. e-Pub 1999. PMID: 10637452.
Li S, Wilkinson MF. Site-directed mutagenesis: a two-step method using PCR and DpnI. Biotechniques 23(4):588-90, 1997. e-Pub 1997. PMID: 9343667.
Li S, Leonard D, Wilkinson MF. T cell receptor (TCR) mini-gene mRNA expression regulated by nonsense codons: a nuclear-associated translation-like mechanism. J Exp Med 185(6):985-92, 1997. e-Pub 1997. PMID: 9091590.
Li S, Ke S, Budde RJ. The C-terminal Src kinase (Csk) is widely expressed, active in HT-29 cells that contain activated Src, and its expression is downregulated in butyrate-treated SW620 cells. Cell Biol Int 20(11):723-9, 1996. e-Pub 1996. PMID: 8979366.
Carter MS, Li S, Wilkinson MF. A splicing-dependent regulatory mechanism that detects translation signals. EMBO J 15(21):5965-5975, 1996. e-Pub 1996. PMID: 8918474.
Maiti S, Doskow J, Li S, Nhim RP, Lindsey JS, Wilkinson MF. The Pem homeobox gene. Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing. J Biol Chem 271(29):17536-46, 1996. e-Pub 1996. PMID: 8663309.
Carter MS, Li S, Wilkinson MF. T cell receptor mRNA regulation: A proofreading mechanism. FASEB Journal 10(6):A-1042, 1996. e-Pub 1996.
Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 270(48):28995-9003, 1995. e-Pub 1995. PMID: 7499432.
Li S, Sun G, Budde RJ. Production and characterization of monoclonal antibodies against the recombinant p50csk protein tyrosine kinase: a tool for signal transduction research. Hybridoma 14(4):341-6, 1995. e-Pub 1995. PMID: 8522345.
Andrews PK, Li S. Partial Purification and Characterization of β-d-Galactosidase from Sweet Cherry, a Nonclimacteric Fruit. J Agric Food Chem 42(10):2177-2182, 1994. e-Pub 1994.
Li S. Collagen-disrupting TIL-cell therapy for sarcoma. American Society of Pediatric Hematology/Oncology.

Invited Articles

Torrero MN, Li S. Growth factor receptors: targets for gene therapy and immunotherapy for cancer treatment. Gene Therapy and Molecular Biology(8):175-180, 2004. e-Pub 2004.
Li S. IL-12-Based therapy of malignancies. Drugs Today (Barc) 37(9):629-637, 2001. e-Pub 2001. PMID: 12743634.

Review Articles

Zhang S, Rao G, Heimberger A, Li S. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. Cytokine Growth Factor Rev 69:73-79, 2023. e-Pub 2023. PMID: 36085259.
Jia Z, Ragoonanan D, Mahadeo KM, Gill J, Gorlick R, Shpal E, Li S. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front Immunol 13:952231, 2022. e-Pub 2022. PMID: 36203573.
Ragoonanan, D, Sheikh, IN, Gupta, S, Khazal, SJ, Tewari, P, Petropoulos, D, Li, S, Mahadeo, KM. The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Biomedicines 10(9), 2022. e-Pub 2022. PMID: 36140387.
Ragoonanan, D, Khazal, SJ, Abdel-Azim, H, McCall, DC, Cuglievan, B, Tambaro, FP, Ahmad, AH, Rowan, CM, Gutierrez, C, Schadler, KL, Li, S, Di Nardo, M, Chi, TL, Gulbis, A, Shoberu, B, Mireles, ME, McArthur, J, Kapoor, N, Miller, J, Fitzgerald, JC, Tewari, P, Petropoulos, D, Gill, JB, Duncan, C, Lehmann, L, Hingorani, S, Angelo, J, Swinford, R, Steiner, ME, Hernandez Tejada, FN, Martin, PL, Auletta, JJ, Choi, SW, Bajwa, R, Dailey Garnes, NM, Kebriaei, P, Rezvani, K, Wierda, WG, Neelapu, SS, Shpall, E, Corbacioglu, S, Mahadeo, KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
Batth IS, Dao L, Satelli A, Mitra A, Yi S, Noh H, Li H, Brownlee Z, Zhou S, Bond J, Wang J, Gill J, Sholler GS, Li S. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. Int J Cancer 147(12):3550-3559, 2020. e-Pub 2020. PMID: 32506485.
Dao L, Ragoonanan D, Yi S, Swinford R, Petropoulos D, Mahadeo KM, Li S. The Organ Trail: A Review of Biomarkers of Organ Failure. Front Oncol 10:579219, 2020. e-Pub 2020. PMID: 33262945.
Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann L, Duncan C, Zantek N, Vittorio J, Angelo J, McArthur J, Schadler KL, Chan S, Tewari P, Khazal SJ, Auletta JJ, Choi SW, Shoberu B, Kalwak K, Harden A, Kebriaei P, Abe J, Li S, Moffet J, Abraham S, Tambaro FP, Kleinschmidt K, Richardson PG, Corbacioglu S. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome. Lancet Haematol 7(1):e61-e72, 2020. e-Pub 2020. PMID: 31818728.
Batth IS, Mitra A, Rood S, Kopetz S, Menter D, Li S. CTC analysis: an update on technological progress. Translational Research 212:14-25, 2019. e-Pub 2019. PMID: 31348892.
Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer 7(1):154, 2019. e-Pub 2019. PMID: 31208461.
Bai W, Kuang T, Chitrakar C, Yang R, Li S, Zhu D, Chang L. Patchable micro/nanodevices interacting with skin. Biosens Bioelectron 122:189-204, 2018. e-Pub 2018. PMID: 30265969.
Gu S, Nguyen BN, Rao S, Li S, Shetty K, Rashid A, Shukla V, Deng CX, Mishra L, Mishra B. Alcohol, stem cells and cancer. Genes Cancer 8(9-10):695-700, 2017. e-Pub 2017. PMID: 29234487.
Rao S, Zaidi S, Banerjee J, Jogunoori W, Sebastian R, Mishra B, Nguyen BN, Wu RC, White J, Deng C, Amdur R, Li S, Mishra L. Transforming growth factor-β in liver cancer stem cells and regeneration. Hepatol Commun 1(6):477-493, 2017. e-Pub 2017. PMID: 29404474.
Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 28(3):468-477, 2017. e-Pub 2017. PMID: 27998963.
Lu Y, Li S, Zhu S, Gong Y, Shi J, Xu L. Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer. Biol Proced Online 19(1):2, 2017. e-Pub 2017. PMID: 28331435.
Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol 35(4):325-339, 2016. e-Pub 2016. PMID: 25259408.
Mitra A, Mishra L, Li S. EMT, CTCs, and CSCs in tumor relapse and drug-resistance. Oncotarget 6(13):10697-10711, 2015. e-Pub 2015. PMID: 25986923.
Yan J, Li S. The role of the liver in sepsis. Int Rev Immunol 33(6):498-510, 2014. e-Pub 2014. PMID: 24611785.
Wang X, Li S. Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochimica et Biophysica Acta - Reviews on Cancer 1846(1):13-25, 2014. e-Pub 2014. PMID: 24709009.
Dibra D, Mishra L, Li S. Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship. Biochim Biophys Acta 1846(1):152-160, 2014. e-Pub 2014. PMID: 24821201.
Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 31(6):347-354, 2013. e-Pub 2013. PMID: 23597659.
Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 9(9):530-8, 2012. e-Pub 2012. PMID: 22710573.
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68(18):3033-46, 2011. e-Pub 2011. PMID: 21637948.
Reed SD, Li S. Electroporation Advances in Large Animals. Curr Gene Ther 9(4):316-26, 2009. e-Pub 2009. PMID: 19545229.
Craig R, Li S. Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs. Mini Rev Med Chem 6(7):757-64, 2006. e-Pub 2006. PMID: 16842125.
Li S. Electroporation gene therapy: new developments in vivo and in vitro. Curr Gene Ther 4(3):309-316, 2004. e-Pub 2004. PMID: 15384944.
Li S, Benninger M. Applications of muscle electroporation gene therapy. Curr Gene Ther 2(1):101-5, 2002. e-Pub 2002. PMID: 12108971.
Li S, Wilkinson MF. Nonsense surveillance in lymphocytes?. Immunity 8(2):135-41, 1998. e-Pub 1998. PMID: 9491995.

Editorials

Li, S. Preface. Methods in Molecular Biology 2050:v, 2020.
Patel, R, Traylor, JI, Latha, K, Heimberger, AB, Li, S & Rao S, G. Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opinion on Therapeutic Targets 23(8):647-649, 2019. PMID: 31167575.
Mitra A, Cutrera J, Mishra L, Li S. Reply. Hepatology 56(6):2425, 2012.
Li S. The Possible Cellular Mechanism for Extending Lifespan. Biological Procedures Online 11(1):1-2, 2009.
Li S. Electroporation gene therapy. Preface. Methods Mol Biol 423:v-vii, 2008. PMID: 18453074.

Abstracts

Li S. Collagen-disrupting TIL-cell therapy for sarcoma. American Society of Pediatric Hematology/Oncology (ASPHO) Conference 2026. e-Pub 2025.
Li S. FGL2-targeted T cell vaccine for inducing tumor-specific resident memory T cells in brains and rejecting tumor cell relapse. 2023 SNO/ASCO CNS Cancer Conference, 2023. e-Pub 2023.
Li S. FGL2-targeted T cell vaccine for inducing tumor-specific resident memory T cells in brains and rejecting tumor cell relapse. Neuro-oncol. adv, SNO/ASCO CNS Cancer Conference Annual Meeting 2023, 2023. e-Pub 2023.
Hu J, Lazar A, Ingram D, Wang W, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. attIL12-T cell therapy destructs cancer-associated fibroblasts and extracellular matrix in heterogenous osteosarcoma xenograft models. AACR 2023 Annual Meeting, 2023. e-Pub 2023.
Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao LH, Xia X, Fowlkes NW, Zhang Z, Mahadeo KM, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1):e003633, 2022. e-Pub 2022. PMID: 35027427.
Dao L, Li S. Cell-surface vimentin positive circulating tumor cells serve as a diagnostic and prognostic indicator in pediatric sarcoma patients. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
Zhao Q, Hu J, Cutrera JJ, Mitra A, Xia X, Li AS. CHP-IL12 combined with surgery suppresses tumor metastasis and prolongs survival 78(13), 2018. e-Pub 2018.
Li S. NKG2D ligand-inducing immune therapy plus NKG2D+CD8+T Cell therapy overcomes chemoresistance in tumors. SITC 32nd Annual Meeting, National Harbor, MD, 2017. e-Pub 2017.
Li H, Qing M, Noh H, I-S B, Somaiah N, K-E T, Xia X, F-J H, Wang R, and Li S. The first circulating tumor cell detection technique from frozen PBMC's. AACR Meeting - Washington, DC - April 3, 2017, 2017. e-Pub 2017.
Noh H, Yan J, Kong L, Gabrusiewicz K, Xia X, A-B H, Li S. Cell surface vimentin targeted mAb 86C increases sensitivity to temozolomide mediated cell death in glioma stem cells. AACR Meeting - Washington, DC - April 4, 2017 77(13), 2017. e-Pub 2017.
Noh H. Cell surface vimentin targeted mAb 86C increases sensitivity to temozolomide mediated cell death in glioma cells. 2017 AACR Annual Meeting, Washington, DC, 2017. e-Pub 2017.
Batth IS. Cell surface vimentin is a novel marker for CTC detection in neuroblastoma. 2017 AACR Annual Meeting, Washington, DC, 2017. e-Pub 2017.
Yan J. Fibrinogen-like protein 2 drives malignant tumor progression in glioma. 2017 AACR Annual Meeting, Washington, DC, 2017. e-Pub 2017.
Yan J, Gabrusiewicz K, Xia X, Heimberger AB, Li S. FGL2 promotes tumor progression via inducing TIGIT expression on T cells in tumor microenvironment of glioma. Immunology 2016, AAI, Seattle, WA, 2016. e-Pub 2016.
Li S. Cell Surface Vimentin (CSV) Serves as Markers and Targets for EMT, Stem Cancer Cell and Metastatic Cells, 2015. e-Pub 2015.
Mitra A, Yan J, Xueping X, Mishra L, Li S. IL30: A biological cytokine provides hepatic protection in chronic inflammation mediated liver fibrosis. World Hepatitis 2015 Conference, 2015. e-Pub 2015.
Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Mishra L, Li S. Alleviation of sepsis in osteosarcoma-bearing mice via immunomodulatory cytokine interleukin-30 treatment. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
Satelli A, Brownlee Z, Noh H, Meng QH, Kopetz S, Overman M, Li S. Detection of PD-L1 in cell surface vimentin positive circulating tumor cells is associated with poor survival in cancer patients. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
Hu J, Xia X, Kleinerman KS, Li S. CD8_T cell mediated tumor-specific induction of the NKG2D ligands to trigger NKG2D-dependent tumor cell death in vivo. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
Menon VK, Raju G, Chen J, Su X, Majumdar A, Li S, Shetty K, Wu X, Weston B, Miller E, Stroehlein JR, Davila M, Shafi M, Rashid A, Kallakury BV, Thirumurthi S, McMurray J, Lin SH, Mishra L. The Genomic Landscape of Human Colon Adenomas Reveals Early Driver Mutations and a TGF-β-CEA regulated profile 148(4):S353-S354, 2015. e-Pub 2015.
Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Intratumoral Chemo Gene Therapy with Interleukin 12: Results of a Clinical Trial in Canines. ASGCT 17th Annual Meeting, May 21-24, 2014 in Washington, DC, 2014. e-Pub 2014.
Chen J, J-S C, Gi YJ, Katz L H, J-H S, Phan L M, Jogunoori W, Shukla V, Mishra B, Li S, Javle M, M-C H, Mishra L. TGF-β regulated E3 ligase are novel therapeutic targets for primary liver cancer. DDW 2014 Digestive Disease Week, Chicago, Illinois, 2014. e-Pub 2014.
Satelli A, LeeZB, Xia X, Ludwig J, Torres KE, Somaiah N, Gordon N, Zweidler-McKay PA, Bitar ND, Tomaras M, Foglesong JS, Kleinerman ES, Li S. "Universal maker for circulating tumor cell detection from pediatric-type of tumors. American Society of Pediatric Hematology/Oncology 27th Annual Meeting, May 14-17 in Chicago, IL, 2014. e-Pub 2014.
Cutrera J, Xia X, King G, Jones P, Kicenuik K, Li S. Electroporation-mediated Chemo-Gene Therapy in Canine Cancer Patients. World Biotechnology Congress 2013, Boston, MA, 2013. e-Pub 2013.
Satelli A, Mitra A, Cutrera JJ, Xia X, Denada D, Lev Chelouche D, Overman MJ, Lee E, Li S. Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells. American Association for Cancer Research (AACR) 2013 Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Dibra D, Newman M, Cutrera J, Li S. The role of IL27 as a driver of skin carcinogenesis. American Association for Cancer Research (AACR) 2013 Annual Meeting, 2013. e-Pub 2013.
Hu J, Zhu S, Xia X, Kleinerman ES, Li S. Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+T cell infiltration to tumors and inhibition of tumor progression. American Association of Cancer Research (AACR) 2013 Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Cutrera J, Johnson B, Mitra A, Xia X, Li S. Inhibition of Metastasis from Targeted Interleukin 12 Immunotherapy and Revelation of the Mechanism by Cell Profiling. ASGCT 2012 Annual Meeting, Philadelphia, PA, 2012. e-Pub 2012.
Hu J, Zhu S, Li S. Regulation of NKG2D expression and NKG2D-positive T cell tumor-specific trafficking by doxorubicin and IL-12 in vivo. AACR Annual Meeting 2012 in Chicago, IL, 2012. e-Pub 2012.
Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. IL30-Anovel Anti-Inflammatory Cytokine Candidate for Prevention and Treatment of Inflammatory Cytokine-Induced Liver Injury. Annual American Association of Immunology Meeting, San Francisco, CA, 2011. e-Pub 2011.
Hu J, Li S. Herceptin trimers linked by EDC could boost direct tumor cell death and overcome resistance to trastuzumab treatment via programmed tumor cell necrosis. Annual AACR Meeting, Orlando, FL, 2011. e-Pub 2011.
Cutrera J, Dibra D, Xia X, Reed S, Hasan A, Li S. Development of a Tumor-Targeted-Cytokine Gene Therapy for Systemic Treatment of Malignant Disease. ASGCT 2010 annual Meeting, Washington, DC, 2010. e-Pub 2010.
Dibra D, Cutrera J, Xia X, Li S. WSX1 Expression in Lewis Lung Carcinoma Promotes Tumor Growth. 101st Annual AACR Meeting in Washington, DC, 2010. e-Pub 2010.
Li S. Programmed cytokine gene therapy for treating highly malignant tumors. 12th Annual Meeting of the American Cancer Society of Gene Therapy Poster Presentation, San Diego, CA, 2009. e-Pub 2009.
Dibra D, Cutrera J, Xia X, Birkenbach MP, Li S. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. AACR 2009 Annual Meeting, Denver, CO, 2009. e-Pub 2009.
Li S. Experience with treatment of tumors in dogs by electroporation chemogene therapy. 11th Annual Meeting of the American Society of Gene Therapy Oral Presentation, Boston, MA, 2008. e-Pub 2008.
Li S. Electroporation gene therapy for treating tumors. 10th Annual Meeting of the American Society of Gene Therapy Oral Symposium Presentation, Seattle, WA, 2007. e-Pub 2007.
Li S. Tumor anchored IFNalpha gene therapy for treating tumors. 9th Annual Meeting of the American Society of Gene Therapy Poster Presentation, Denver, CO, 2006. e-Pub 2006.
Torrero MN, LI S. Combination Therapy with Bleomycin and IL-12 Gene Induces Regression of Breast Cancer. 8th Annual Meeting of the American Society of Gene Therapy Poster Presentation, St. Louis, MO, 2005. e-Pub 2005.
Liu J, Li S. Regression of squamous cell carcinoma by single administration of IL-12 and B7.1 genes via electroporation. 8th annual Meeting of the American Society of Gene Therapy Poster Presentation, St. Louis, MO, 2005. e-Pub 2005.
Li S. Induction of anti-tumoral immune response and IFN-regulated factors by delivery of control DDNA. 8th Annual Meeting of the American Society of Gene Therapy Poster Presentation, St. Louis, Mo, 2005. e-Pub 2005.
Li S. Therapeutic efficacy and cellular mechanism mediated by intratumoral and intramuscular IL-12 electrogenetherapy. 7th Annual Meeting of the American Society of Gene Therapy Poster Presentation, Minneapolis, MN, 2004. e-Pub 2004.
Li S. Molecular mechanism of tumor regression and toxicity elicited by local and systemic IL-12 electroporation gene therapy. 6th Annual Meeting of the American Society of Gene Therapy Poster Presentation, Minneapolis, MN, 2004. e-Pub 2004.
Li S. Molecular mechanism of tumor regression and toxicity elicited by local and systemic IL-12 electroporation gene therapy. 5th Annual Meeting of the American Society of Gene Therapy Poster Presentation, Washington, D. C, 2003. e-Pub 2003.
Li S. Regression of tumor growth and induction of long-term anti-tumor memory by IL-12 electro-gene therapy. 5th Annual Meeting of the American Ssociety of Gene Therapy Poster Presentation, Boston, MA, 2002. e-Pub 2002.
Li S, Zhang X, Woodlis J, Breau R, Suen J, Hanna E. Intramuscular electroporation IL-12 gnee therapy for treatment of SCC locted at distant site. 4th Annual Meeting of the American Society of Gene Therapy Poster Presentation, Seattle, Washington, 2001. e-Pub 2001.
Wang J, Li S, Carter M, Hamilton J, Wilkinson MF. Nonsense codon-dependent induction of alternatively spliced transcripts. Cold Spring Harbor Translation Meeting Poster Presentation, Cold Spring Harbor, NY, 2000. e-Pub 2000.
Vock VM, Want J, Li S, Wilkinson MF. The involvement of ribosomes in nonsense-mediated downregulation. 5th Annual International RNA Meeting Poster Presentation, Madison, WI, 2000. e-Pub 2000.
Li S, Zhang X, Woodlis J, Breau R, Suen J, Hanna, E. IFN-a gene therapy for squamous cell carcinoma using muscle electroporation delilvery. 91st AACR Annual Meeting Poster Presentation, San Francisco, CA, 2000. e-Pub 2000.
Hamilton JI, Carter MS, Li S, Wang J, Wilkinson MF. A T-cell receptor surveillance mechansim. 18th Annual Texas Regional Immunology Conference Oral Presentation, Galveston, TX, 1999. e-Pub 1999.
Gudikote J, Li S, Wilkinson, MF. Is nonsense codon-mediated decay regulated by nonsense promoting elements. Eukaryotic mRNA Processing Meeting Poster Presentation, Cold Spring Harbor, New York, 1999. e-Pub 1999.
Vock V, Li S, Wilkinson MF. Nonsense surveillance in lymphocytes,. Mid-winter Conference of Immunologists Oral Presentation, Asilomar, CA, 1999. e-Pub 1999.
Li S, Wilkinson MF. Nonsense surveillance in lymphoctyes. 15th Annual Texas Regional Immunology conference Oral Presentation, Galveston, TX, 1997. e-Pub 1997.
Li S, Wilkinson MF. A putative surveillance mechanism that down regulates aberrant transcript bearing premature termination codons. International RNA Society Annual Meeting Oral Presentation, Banff, Alberta, Canada, 1997. e-Pub 1997.
Li S, Carter MS, Wilkinson MF. T cell receptor mRNA regulation: a scanning mechanism that detects premature nonsende codons. 14th Annual Texas Regional Immunology Conference Oral Presentation, San Antonio, Texas, 1996. e-Pub 1996.
Maiti SM, Doskow J, Li S, Nhim R, Lindsey JS, Wilkinson MF. The Pem Homeobox gene displays androgen-dependent alternative promoter usage and tissue-specific RNA splicing. 10th International Congress of Endocrinology, San Francisco, CA Poster Presentation, 1996. e-Pub 1996.
Carter MS, Li S. A doenstream intron is essential for nonsense codon-mediated regulation in the nucleus. International RNA Society Annual Meeting, Univesity of Wisconsin Poster Session, Madison, Wisconsin, 1996. e-Pub 1996.
Li S, Carter MS, Wilkinson MF. Multiple exon skipping and alternative splice donor/acceptor usage induced by nonsense condons. International RNA Society Annual Meeting, University of Wisconsin, Oral Presentation, 1996. e-Pub 1996.
Carter MS, Li S, Wilkinson MF. T cell receptor mRNA regulation: A proofreading mechanism. FASEB Journal 10(6):A1042, 1996. e-Pub 1996.
Li S, Andrews PK, Patterson ME. Effects of ethephon on the respiration and ethylene evolution of sweet cherry (Prunus avium L.) fruit at different development stages. Postharvest Biology and Technology 4(3):235-243, 1994. e-Pub 1994.
Satelli A, Brownlee Z, Overman M, Kopetz S, Meng QH, Li S. A universal marker for the detection of epithelial-mesenchymal transitioned circulating tumor cells and their prognostic relevance in epithelial cancers. AACR Annual Meeting 2014 in San Diego, CA.
Yang Q, Hu J, Jia Z, Dao L, Xia X, Gorlick R, Li S. Displaying tumor-targeted IL-12 (attIL12) on PBMC surface may serve as a new approach for treating heterogenous solid tumors without causing immune toxicity. 37th Annual Meeting and Pre-Conference Society for Immunotherapy.
Latha K, Yan J, Yang Y, L-V G, Kong L, Manyam G, Ezhilarasan R, Wang Q, E-P S, Xu J, R-E D, Huang S, G-N F, Rao A, A-B H, Li S, Rao G. Fibrinogen-like protein 2 drives malignant tumor progression in glioma. AACR Meeting - Washington, DC - April 5, 2017.
Batth I. Cell surface vimentin in a novel marker for CTC detection in neuroblastoma. AACR Meeting - Washington, DC - April 3, 2017.
Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting.
Abhisek M, Satelli A, Xia X, Li S. Discovery and characterization of EMT positive and chemo-resistant novel population of HCC like stem cells. AACR Annual Meeting 2014 in San Diego, CA.
Dibra D, Xia X, Newman M, Keenan C, Li S. IL27 promotes papilloma formation via inducing a pro-inflammatory milieu in the skin. AACR Annual Meeting 2014 in San Diego, CA.
Chen J, J-S C, Gi YJ, Katz L H, J-H S, Phan L M, Jogunoori W, Shukla V, Mishra B, Li S, Javle M, M-C H, Mishra L. TGF-β regulated E3 ligase are novel therapeutic targets for primary liver cancer. Digestive Disease Week (DDW), Chicago, Illinois.
Menon VK, Raju G, Chen J, Su X, Majumdar A, Li S, Shetty K, Wu X, Weston B, Miller E, Stroehlein JR, Davila M, Shafi M, Rashid A, Kallakury BV, Thirumurthi S, McMurray J, Lin SH, Mishra L. The Genomic Landscape of Human Colon Adenomas Reveals Early Driver Mutations and a TGF-β-CEA regulated profile. Digestive Disease Week.
Mitra A, Xia X, Li S, Mishra L. Induction of EMT positive liver cancer stem cells by IL6 treatment in Beta ?2SP +/- mice. Keystone Symposia.
Li S. Neutralizing the toxicity and boosting the anti-tumor efficacy of both CAR-/TCR-T cells and IL12 via minimal genetic engineering IL12 and cell membrane anchoring. 7th International Conference on Cancer Research & Drug Development in Baltimore, MD.
Li S. attIL12-T cell therapy for simultaneously disrupting stroma/tumors and induction of endogenous TCR-T cells. 30th International Society for Cell & Gene Therapy Annual Meeting.
Jin Y, Li S. Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. American Association of Immunologists (AAI) IMMUNOLOGY.
Hu J, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T-cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. American Association of Immunologists (AAI) IMMUNOLOGY.

Book Chapters

Batth, IS, Li, S. Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy, 169-178, 2020.
Batth IS, Li S. Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy. In: Current Advances in Osteosarcoma. 2nd. Springer, Cham, 169-178, 2020.
Cutrera J, King G, Jones P, Gumpel E, Xia X, Li S. Managing Local Swelling Following Intratumoral Electro-Chemo-Gene Therapy. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 2nd. Humana Press, 233-239, 2014.
Hu J, Cutrera J, Li S. The Impact of Non-electrical Factors on Electrical Gene Transfer. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 2nd. Humana Press, 47-54, 2014.
Hu J, Li S. Electroporation formulation for cell therapy. In: Electroporation Protocols. Humana Press, 55-60, 2014.
Cutrera JJ, King G, Jones P, Gumpel E, Xia X, Li S. Managing local swelling following intratumoral electro-chemo-gene therapy. In: Electroporation Protocols. Humana Press, 233-239, 2014.
Hu J, Cutrera JJ, Li S. The impact of non-electrical factors on electrical gene transfer. In: Electroporation Protocols. Humana Press, 47-54, 2014.
Cutrera J, Li S. Passive and active tumor homing cytokine therapy. In: Targeted Cancer Immune Therapy. Springer, 97-113, 2009.
Dibra D, Li S. Role of IL12 family in regulation of antitumor immune response. In: Targeted Cancer Immune Therapy. Springer, 3-18, 2009.
Dibra D, Li S. Role of Il12 family in regulation of antitumor immune response. In: Tumor-targeted Immune Therapy. Springer, Inc, 2009.
Cutrera J, Li S. Passive and active tumor Homing Cytokine Therapy. In: Tumor-targeted Immune Therapy. Springer, Inc, 2009.
Cutrera J, Li S. Treatment of spontaneous tumors in dogs and cats by co-administration of bleomycin and IL-12 using electroporation delivery. In: Electroporation protocols: Experimental and Clinical Medicine. Humana Press, 2008.
Li, S. Optimal gene delivery to tumors. In: Electroporation protocols: Experimental and Clinical Medicine. Humana Press, 2008.
and Li ZS, S. Muscle-based gene delivery via electroporation. In: Electroporation protocols: Experimental and Clinical Medicine, 2008.
and Li TM, S. Systemic delivery of IL-12 gene plus cyclophosphamide for inhibiting tumor growth. In: Electroporation protocols: Experimental and Clinical Medicine. Humana Press, 2008.
Li, S. Optimizing electrotransfection of mammalian cells in vitro. In: Gene Transfer Delivery and Expression of DNA and RNA. Cold Spring Harbor Laboratory, 419-426, 2007.
Li, S. Strategies for designing tumor-targeted vector via translational approach. In: Genetic Vector Commentary:. Genetic Vector Nova Science Publishers, 2007.
MacLaughlin F, Li S, Li Y, Fewel J, Rolland A, and Smith L. Plasmid Gene Delivery: Advantages and Limitations. In: Targeting of Drugs: Strategies for Gene Constructs and Delivery. IOS Press, the Netherlands, 81-91, 2000.

Books (edited and written)

Li S, Chang L, Teissie J. Electroporation Protocols: Microorganism, Mammalian system, and Nanodevice. Ed(s) 3rd Edition. Humana Press, 2019.
Li S, Cutrera J, Heller R, Teissie J. Electroporation protocols: Experimental and Clinical Gene Medicine. Ed(s) 2nd. Humana Press, 2014.
Lustgarten I, Cui Y, Li S. Targeted Cancer Immune Therapy. Ed(s) 1. Springer, 2009.
Li S. Electroporation protocols: Experimental and Clinical Gene Medicine. Ed(s) 1st. Humana Press, 2008.

Letters to the Editor

Mitra A, Cutrera J, Mishra L, Li S. IL6 vs IL30 for liver protection: The risk of IL6 as a protectant in cancer patients. Hepatology 56: 2425, 2012.
Mitra A, Cutrera J, Mishra L, Li S. Reply: Role of interleukin-30 as a modulator of transcription signaling in liver injury. Hepatology 56: 2425, 2012.

Web Publications

Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Accelerating Cancer Immunotherapy Research (ACIR): In the Spotlight... Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas, 2025.
Zaky W, Ragoonanan D, Batth I, Dao L, Wang J, Xia X, Daw NC, Gill JB, Khatua S, Li S. National Institute of Biomedical Imaging and Bioengineering - Automated liquid biopsy detects brain tumor cells in children, 2023.

Patents

Li S, Yan J, Xia X, Hu J, Zhao Q, Parker D. FGL2 Monoclonal Antibodies And Their Use In Treating Malignant Tumors. Patent Number: HK40023906.
FGL2 Monoclonal Antibodies and Their Use in Treating Malignant Tumors. Patent Number: UTSC.P1322US.
Specific Detection Tool for Mesenchymal and Epithelial-Mesenchymal transformed Circulating Tumor Cells. Patent Number: US10,329,353 B2.
Specific Detection Tool For Mesenchymal And Epithelial-Mesenchymal Transformed Circulating Tumor Cells. Patent Number: CN 105209489.
Specific Detection Tool for Mesenchymal and Epithelial-Mesenchymal Transformed Circulating Tumor Cells. Patent Number: EP 2964672 B1/602014054931.4.
Carcinoma Homing Peptide (CHP), Its Analogs, and Methods of Using. Patent Number: US 9,657,077 B2.
Li S, Yan J, Xia X, Hu J, Zhao Q, Parker D. FGL2 Monoclonal Antibodies and their use in Treating Malignant Tumors. Patent Number: ZL 2018800418860.
Specific Detection Tool for Mesenchymal and Epithelial-Mesenchymal Transformed Circulating Tumor Cells. Patent Number: EP 2964672 B1.
Specific Detection Tool for Mesenchymal and Epithelial-Mesenchymal Transformed Circulating Tumor Cells. Patent Number: 2018-109484/JP 2015-561585.
T Cells Expressing Membrane-Anchored IL-12 For The Treatment Of Cancer. Patent Number: US20220380429A1.

Less

CV information above last modified March 26, 2026

Shulin Li, PhD

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Web Publications

Patents

Patient Reviews

Related Links

Shulin Li Laboratory

Pediatrics division

Help #EndCancer

Shulin Li, PhD

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Web Publications

Patents

Patient Reviews

Request an Appointment

Related Links

Shulin Li Laboratory

Pediatrics division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson